Impax Must Pay For GSK Wellbutrin Settlement, Teva Says
Teva Pharmaceuticals said that misrepresentations from drugmaker Impax Laboratories about the bioequivalence of a now-discontinued generic version of antidepressant Wellbutrin left it exposed to hundreds of millions of dollars in damages...To view the full article, register now.
Already a subscriber? Click here to view full article